Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

Mounjaro, a new treatment for Type 2 diabetes and obesity, has been launched in India after CDSCO approval. The drug, ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Some industries have escaped these moves by the administration, at least for now. One of them is the pharmaceutical industry.

We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to ...

Eli Lilly and Co. is suing an Indianapolis-based weight-loss clinic it says is improperly selling Lilly’s hugely popular ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...